Eli Lilly and Company

New Capabilities

Actively pursuing GLP-1 addiction trials

Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A study of more than 600,000 United States veterans, published March 4 in The BMJ, found that people taking GLP-1 medications were 14 percent less likely to develop a new substance use disorder and, if they already had one, experienced 50 percent fewer substance-related deaths and 39 percent fewer overdoses.

Updated Mar 6

Rule Changes

Reduced insulin prices by 70% in 2023

On January 1, 2026, two unprecedented insulin programs launched simultaneously: nonprofit Civica Rx began distributing insulin glargine pens for $55 per box, while California became the first state to sell its own CalRx-branded insulin at the same price point—both undercutting branded products by up to 90%. The coordinated launches mark the first major breach in a pricing fortress built by three pharmaceutical giants who control 90% of the U.S. insulin market. Unlike existing insulin, these products require no insurance forms, no rebates, no hidden markups. Just one transparent price available to anyone.

Updated Feb 10

Rule Changes

Negotiating partner in BALANCE model

Medicare has been banned from covering weight loss drugs since 2003. CMS launched the BALANCE voluntary model in December 2025 to work around the law—negotiating $50-per-month access to Ozempic, Wegovy, and similar blockbusters for 10% of Medicare enrollees starting July 2026. The workaround: don't call it weight loss coverage, call it treatment for chronic disease with specific comorbidities. Manufacturer applications closed January 8, 2026, with negotiations continuing through February 28.

Updated Jan 14

New Capabilities

Partner in diagnostic development and maker of Kisunla

For decades, diagnosing Alzheimer's meant either a $5,000 brain scan with radiation exposure or a painful spinal tap. In October 2025, the FDA cleared Roche's blood test for use in primary care—a simple blood draw that rules out Alzheimer's 97.9% of the time. It's the second blood test approved in five months, transforming a diagnosis that once required specialists and imaging centers into something your family doctor can order.

Updated Jan 9